Earlier today, Immune Therapeutics, Inc. (OTCQB: IMUN)
announced that Nigeria’s National Agency for Food and Drug Administration and
Control (NAFDAC) has approved the company’s patented Lodonal™ as an
over-the-counter, non-toxic adjunct therapy in the treatment of HIV/AIDS. With
this approval, IMUN’s distribution partners, AHAR Pharma and GB Pharma
Holdings, will now be able to launch nationwide marketing and sales programs
for the breakthrough immunotherapy, creating a new revenue stream for IMUN and
contributing to health security in Nigeria.
“Receiving approval of our affordable non-toxic
immunodeficiency treatment Lodonal is a significant company milestone,” Noreen
Griffin, chief executive officer of IMUN, stated in this morning’s news
release. “Supported by a new and growing body of clinical research, we expect
Lodonal will be increasingly proven as an effective treatment for patients
suffering from a comprised immune system and other autoimmune conditions as it
prepares for commercialization.”
The NAFDAC approval comes as a result of the successful
completion of a 90-day bridging study conducted by AHAR Pharma at the State
Specialist Hospital in Nigeria. The results of the Nigerian study were
consistent with IMUN’s previous clinical trials of Lodonal, yielding an average
increase of 44 percent in CD4 count in the treatment group, as compared to an
increase of just 11 percent in the control group. Higher CD4 counts have been
linked to increased ability to fight HIV and other infections. According to the
U.S. Department of Health & Human Services (http://dtn.fm/QU4dS), CD4 count
is the ‘most important laboratory indicator of how well [the] immune system is
working and the strongest predictor of HIV progression’.
The market potential of Lodonal in Nigeria, which is
Africa’s leading economy with more than 175 million people, is immense. Among
its many benefits, Lodonal is cost-effective and easy to administer, requiring
just a single daily oral dose. In addition to affordably improving the quality
of life of patients, the therapy also offers a compelling economic benefit to
national health care systems, as it is designed to produce a significant
reduction in opportunistic infections.
The path of destruction created by the HIV/AIDS epidemic in
sub-Saharan Africa is staggering. According to AVERT (http://dtn.fm/hPF5o), a
global provider of HIV/AIDS education, roughly 24.7 million people in the
sub-Saharan region were living with HIV in 2013. Among those individuals, just
39 percent of adults were on antiretroviral treatments. When combined with the
knowledge that an estimated 75 percent of adults in the region with HIV who are
currently accessing antiretroviral treatments have not yet achieved viral
suppression, the critical need for IMUN’s innovative adjunct therapy is clearly
demonstrated.
“While we finalize the registration process… we will focus
on distribution throughout Nigeria,” continued Griffin. “Simultaneously we will
be working to leverage the successful clinical trial results and NAFDAC
approval to expedite the approval and distribution into the many other African
nations that have been devastated by HIV/AIDS for the past 17 years.”
Learn more by visiting www.immunetherapeutics.com
About QualityStocks
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to find, evaluate, and learn more about investing in these companies.
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to find, evaluate, and learn more about investing in these companies.
Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net
The Quality Stocks Daily Blog http://blog.qualitystocks.net
The Quality Stocks Daily Videos http://videocharts.qualitystocks.net
The Quality Stocks “Ones to Watch” http://gotstocks.qualitystocks.net
Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
No comments:
Post a Comment